Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All povidone‑iodine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPovidone-IodinePovidone-Iod.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in patients with COVID-19

Matsuyama et al., Scientific Reports, doi:10.1038/s41598-022-24683-8, jRCT1051200078
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Viral infectivity, culture 69% Improvement Relative Risk Viral clearance, PCR 38% primary Povidone-Iodine  Matsuyama et al.  EARLY TREATMENT  RCT Is early treatment with povidone-iodine beneficial for COVID-19? RCT 279 patients in Japan (November 2020 - March 2021) Improved viral clearance with povidone-iodine (p=0.025) c19early.org Matsuyama et al., Scientific Reports, Nov 2022 Favorspovidone-iodine Favorscontrol 0 0.5 1 1.5 2+
PVP-I for COVID-19
13th treatment shown to reduce risk in February 2021
 
*, now with p = 0.000000004 from 21 studies.
Lower risk for mortality, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
RCT 430 COVID+ patients in Japan, showing significantly lower viral infectivity from culture, and significantly faster PCR viral clearance with PVP-I.
For days 2-4 the study compares treatment with PVP-I vs. water (on day 5 both groups received PVP-I). Most patients were asymptomatic. 4 times per day mouthwashing and gargling with 20mL of 15-fold diluted PVP–I 7% or water.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
viral infectivity, 69.0% lower, RR 0.31, p = 0.03, treatment 4 of 139 (2.9%), control 13 of 140 (9.3%), NNT 16, viral infectivity from culture, day 5.
risk of no viral clearance, 38.0% lower, HR 0.62, p = 0.01, treatment 139, control 140, inverted to make HR<1 favor treatment, day 5, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Matsuyama et al., 28 Nov 2022, Randomized Controlled Trial, Japan, peer-reviewed, mean age 45.1, 4 authors, study period 30 November, 2020 - 17 March, 2021, trial jRCT1051200078. Contact: matsuyamaak@opho.jp.
This PaperPovidone-Iod..All
A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in patients with COVID-19
Akifumi Matsuyama, Hanayuki Okura, Shyoji Hashimoto, Toshio Tanaka
Scientific Reports, doi:10.1038/s41598-022-24683-8
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic reagent that has been used for over 50 years. The purpose of this study is to look into the effect of gargling with PVP-I gargling on virus clearance and saliva infectivity in COVID-19. A prospective, randomized, open-label trial of intervention with PVP-I was conducted at three quarantine facilities in Osaka, Japan, enrolling adolescents and adults with asymptomatic-to-mild COVID-19. Patients were randomly allocated to the early and late intervention group at a 1:1 ratio. The early group gargled with PVP-I from days 2 to day 6; the late group gargled with water first, then with PVP-I from day 5 after sampling till day 6. The primary and secondary endpoints were viral clearance for SARS-CoV-2 using RT-qPCR at days 5 and 6, respectively, and the investigational endpoint was saliva infectivity clearance on day5. We enrolled 430 participants, with 215 assigned to each group, and 139 in the early group and 140 in the late had a positive saliva RT-qPCR test on day 2. On day 5, the early group had a significantly higher RT-qPCR negative rate than that of the late group (p = 0.015), and the early had a significantly higher clearance rate of infectivity (p = 0.025). During the PVP-I intervention, one participant reported oropharyngeal discomfort. Gargling with PVP-I may hasten virus clearance and reduce viral transmission via salivary droplets and aerosols in patients with asymptomatic-to-mild COVID-19. (Clinical trial registration numbers: jRCT1051200078 and dateof registration: 24/11/2020). The salivary SARS-CoV-2 viral load is thought to play a significant role in the accelerated transmission of coronavirus disease 2019 (COVID-19) 1 . A reduction in salivary viral load is thought to suppress transmission 2 , and some studies have suggested that mouthwash and/or gargling with povidone-iodine (PVP-I) may have an antiseptic effect for SARS-CoV-2, reducing its viral load 3 . However, it is unknown whether gargling with PVP-I would eliminate salivary viral load and infectivity in COVID-19 patients in vivo. PVP-I is a polyvinylpyrrolidone (PVP) and iodine complex that has an antiseptic effect by releasing iodine. Its mechanism of action involves the use of iodine to oxidize microbial components. PVP-I has previously been shown to have an antiseptic effect on SARS-CoV and MERS in vitro 4, 5 , and it was also effective against SARS-CoV-2 6 . A single in vitro gargle with PVP-I reduced the salivary viral load in two of four patients with a high salivary viral load 7 . Although recent studies have confirmed the short-term effects of reducing salivary viral load in a small number of patients with COVID-19 8 , there have been no prospective randomized intervention studies involving PVP-I gargling. The purpose of this study was to see if gargling with PVP-I will reduce viral load and SARS-CoV-2 infectivity in patients with COVID-19. Materials and methods Study design. This was a prospective, randomized,..
Author contributions A.M. had full access to all data in the study. A.M., S.H., and T.T. were responsible for the trial design. A.M. was responsible for the acquisition and analysis of data. H.O. acquired the laboratory data. A.M. drafted the paper. SH. and T.T. revised one. A.M. was responsible for the integrity of the data, the accuracy of the data analysis and decided to publish the manuscript. All authors contributed to conducting the trial. Competing interests The authors declare no competing interests.
References
Anderson, Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease, Infect. Dis. Ther
Ather, Patel, Ruparel, Diogenes, Hargreaves, Coronavirus Disease 19 (COVID-19): Implications for clinical dental care, J. Endod
Bidra, Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidoneiodine oral antiseptic rinse, J. Prosthodont
Burton, Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them, Cochrane Database Syst. Rev
Burton, Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection, Cochrane Database Syst. Rev
Eggers, Eickmann, Zorn, Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA), Infect. Dis. Ther
Eggers, Koburger-Janssen, Eickmann, Zorn, In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/ mouthwash against respiratory and oral tract pathogens, Infect. Dis. Ther
Huang, SARS-CoV-2 infection of the oral cavity and saliva, Nat. Med
Kariwa, Fujii, Takashima, Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents, Jpn. J. Vet. Res
Khan, Parab, Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study, Am. J. Otolaryngol
Killingley, Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge, Nat. Med, doi:10.21203/rs.3.rs-1121993/v1
Martínez Lamas, Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests, Oral Dis, doi:10.1111/odi.13526
Mateos-Moreno, Mira, Ausina-Márquez, Ferrer, Oral antiseptics against coronavirus: In-vitro and clinical evidence, J. Hosp. Infect
Nobukuni, The influence of long-term treatment with povidone-iodine on thyroid function, Dermatology
Seet, Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial, Int. J. Infect. Dis
Seneviratne, Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized control trial in Singapore, Infection
Xu, Saliva: Potential diagnostic value and transmission of 2019-nCoV, Int. J. Oral Sci
Yang, Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities, Proc. Natl. Acad. Sci
{ 'indexed': { 'date-parts': [[2022, 11, 29]], 'date-time': '2022-11-29T05:51:54Z', 'timestamp': 1669701114182}, 'reference-count': 20, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 11, 28]], 'date-time': '2022-11-28T00:00:00Z', 'timestamp': 1669593600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 11, 28]], 'date-time': '2022-11-28T00:00:00Z', 'timestamp': 1669593600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Povidone-iodine (PVP–I) is a broad-spectrum ' 'antiseptic reagent that has been used for over 50\xa0years. The purpose of this study is to ' 'look into the effect of gargling with PVP–I gargling on virus clearance and saliva ' 'infectivity in COVID-19. A prospective, randomized, open-label trial of intervention with ' 'PVP–I was conducted at three quarantine facilities in Osaka, Japan, enrolling adolescents and ' 'adults with asymptomatic-to-mild COVID-19. Patients were randomly allocated to the early and ' 'late intervention group at a 1:1 ratio. The early group gargled with PVP–I from days 2 to day ' '6; the late group gargled with water first, then with PVP–I from day 5 after sampling till ' 'day 6. The primary and secondary endpoints were viral clearance for SARS-CoV-2 using RT-qPCR ' 'at days 5 and 6, respectively, and the investigational endpoint was saliva infectivity ' 'clearance on day5. We enrolled 430 participants, with 215 assigned to each group, and 139 in ' 'the early group and 140 in the late had a positive saliva RT-qPCR test on day 2. On day 5, ' 'the early group had a significantly higher RT-qPCR negative rate than that of the late group ' '(p\u2009=\u20090.015), and the early had a significantly higher clearance rate of infectivity ' '(p\u2009=\u20090.025). During the PVP–I intervention, one participant reported oropharyngeal ' 'discomfort. Gargling with PVP–I may hasten virus clearance and reduce viral transmission via ' 'salivary droplets and aerosols in patients with asymptomatic-to-mild COVID-19. (Clinical ' 'trial registration numbers: jRCT1051200078 and dateof registration: 24/11/2020).</jats:p>', 'DOI': '10.1038/s41598-022-24683-8', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 11, 28]], 'date-time': '2022-11-28T11:05:01Z', 'timestamp': 1669633501000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in ' 'patients with COVID-19', 'prefix': '10.1038', 'volume': '12', 'author': [ {'given': 'Akifumi', 'family': 'Matsuyama', 'sequence': 'first', 'affiliation': []}, {'given': 'Hanayuki', 'family': 'Okura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shyoji', 'family': 'Hashimoto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Toshio', 'family': 'Tanaka', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 11, 28]]}, 'reference': [ { 'issue': '5', 'key': '24683_CR1', 'doi-asserted-by': 'publisher', 'first-page': '892', 'DOI': '10.1038/s41591-021-01296-8', 'volume': '27', 'author': 'N Huang', 'year': '2021', 'unstructured': 'Huang, N. et al. SARS-CoV-2 infection of the oral cavity and saliva. ' 'Nat. Med. 27(5), 892–903 (2021).', 'journal-title': 'Nat. Med.'}, { 'issue': '1', 'key': '24683_CR2', 'doi-asserted-by': 'publisher', 'first-page': '11', 'DOI': '10.1038/s41368-020-0080-z', 'volume': '12', 'author': 'R Xu', 'year': '2020', 'unstructured': 'Xu, R. et al. Saliva: Potential diagnostic value and transmission of ' '2019-nCoV. Int. J. Oral Sci. 12(1), 11 (2020).', 'journal-title': 'Int. J. Oral Sci.'}, { 'key': '24683_CR3', 'doi-asserted-by': 'publisher', 'first-page': '30', 'DOI': '10.1016/j.jhin.2021.04.004', 'volume': '113', 'author': 'MV Mateos-Moreno', 'year': '2021', 'unstructured': 'Mateos-Moreno, M. V., Mira, A., Ausina-Márquez, V. & Ferrer, M. D. Oral ' 'antiseptics against coronavirus: In-vitro and clinical evidence. J. ' 'Hosp. Infect. 113, 30–43 (2021).', 'journal-title': 'J. Hosp. Infect.'}, { 'issue': '3', 'key': '24683_CR4', 'first-page': '105', 'volume': '52', 'author': 'H Kariwa', 'year': '2004', 'unstructured': 'Kariwa, H., Fujii, N. & Takashima, I. Inactivation of SARS coronavirus ' 'by means of povidone-iodine, physical conditions, and chemical reagents. ' 'Jpn. J. Vet. Res. 52(3), 105–112 (2004).', 'journal-title': 'Jpn. J. Vet. Res.'}, { 'issue': '4', 'key': '24683_CR5', 'doi-asserted-by': 'publisher', 'first-page': '491', 'DOI': '10.1007/s40121-015-0091-9', 'volume': '4', 'author': 'M Eggers', 'year': '2015', 'unstructured': 'Eggers, M., Eickmann, M. & Zorn, J. Rapid and effective virucidal ' 'activity of povidone-iodine products against Middle East respiratory ' 'syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara ' '(MVA). Infect. Dis. Ther. 4(4), 491–501 (2015).', 'journal-title': 'Infect. Dis. Ther.'}, { 'issue': '3', 'key': '24683_CR6', 'doi-asserted-by': 'publisher', 'first-page': '669', 'DOI': '10.1007/s40121-020-00316-3', 'volume': '9', 'author': 'DE Anderson', 'year': '2020', 'unstructured': 'Anderson, D. E. et al. Povidone-iodine demonstrates rapid in vitro ' 'virucidal activity against SARS-CoV-2, the virus causing COVID-19 ' 'disease. Infect. Dis. Ther. 9(3), 669–675 (2020).', 'journal-title': 'Infect. Dis. Ther.'}, { 'key': '24683_CR7', 'doi-asserted-by': 'publisher', 'author': 'L Martínez Lamas', 'year': '2020', 'unstructured': 'Martínez Lamas, L. et al. Is povidone iodine mouthwash effective against ' 'SARS-CoV-2? First in vivo tests. Oral Dis. ' 'https://doi.org/10.1111/odi.13526 (2020).', 'journal-title': 'Oral Dis.', 'DOI': '10.1111/odi.13526'}, { 'issue': '2', 'key': '24683_CR8', 'doi-asserted-by': 'publisher', 'first-page': '305', 'DOI': '10.1007/s15010-020-01563-9', 'volume': '49', 'author': 'CJ Seneviratne', 'year': '2021', 'unstructured': 'Seneviratne, C. J. et al. Efficacy of commercial mouth-rinses on ' 'SARS-CoV-2 viral load in saliva: Randomized control trial in Singapore. ' 'Infection 49(2), 305–311 (2021).', 'journal-title': 'Infection'}, { 'issue': '2', 'key': '24683_CR9', 'doi-asserted-by': 'publisher', 'first-page': '249', 'DOI': '10.1007/s40121-018-0200-7', 'volume': '7', 'author': 'M Eggers', 'year': '2018', 'unstructured': 'Eggers, M., Koburger-Janssen, T., Eickmann, M. & Zorn, J. In vitro ' 'bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash ' 'against respiratory and oral tract pathogens. Infect. Dis. Ther. 7(2), ' '249–259 (2018).', 'journal-title': 'Infect. Dis. Ther.'}, { 'issue': '6', 'key': '24683_CR10', 'doi-asserted-by': 'publisher', 'first-page': '529', 'DOI': '10.1111/jopr.13209', 'volume': '29', 'author': 'AS Bidra', 'year': '2020', 'unstructured': 'Bidra, A. S. et al. Rapid in-vitro inactivation of severe acute ' 'respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine ' 'oral antiseptic rinse. J. Prosthodont. 29(6), 529–533 (2020).', 'journal-title': 'J. Prosthodont.'}, { 'issue': '5', 'key': '24683_CR11', 'doi-asserted-by': 'publisher', 'first-page': '584', 'DOI': '10.1016/j.joen.2020.03.008', 'volume': '46', 'author': 'A Ather', 'year': '2020', 'unstructured': 'Ather, A., Patel, B., Ruparel, N. B., Diogenes, A. & Hargreaves, K. M. ' 'Coronavirus Disease 19 (COVID-19): Implications for clinical dental ' 'care. J. Endod. 46(5), 584–595 (2020).', 'journal-title': 'J. Endod.'}, { 'key': '24683_CR12', 'doi-asserted-by': 'publisher', 'author': 'B Killingley', 'year': '2022', 'unstructured': 'Killingley, B. et al. Safety, tolerability and viral kinetics during ' 'SARS-CoV-2 human challenge. Nat. Med. ' 'https://doi.org/10.21203/rs.3.rs-1121993/v1 (2022).', 'journal-title': 'Nat. Med.', 'DOI': '10.21203/rs.3.rs-1121993/v1'}, { 'issue': 'Suppl 2', 'key': '24683_CR13', 'doi-asserted-by': 'publisher', 'first-page': '69', 'DOI': '10.1159/000246034', 'volume': '195', 'author': 'K Nobukuni', 'year': '1997', 'unstructured': 'Nobukuni, K. et al. The influence of long-term treatment with ' 'povidone-iodine on thyroid function. Dermatology 195(Suppl 2), 69–72 ' '(1997).', 'journal-title': 'Dermatology'}, { 'issue': '2', 'key': '24683_CR14', 'doi-asserted-by': 'publisher', 'first-page': '102880', 'DOI': '10.1016/j.amjoto.2020.102880', 'volume': '42', 'author': 'MM Khan', 'year': '2021', 'unstructured': 'Khan, M. M. & Parab, S. R. Tolerability and usability of 0.5% PVP-I ' 'gargles and nasal drops in 6692 patients: Observational study. Am. J. ' 'Otolaryngol. 42(2), 102880 (2021).', 'journal-title': 'Am. J. Otolaryngol.'}, { 'key': '24683_CR15', 'unstructured': 'ADA releases interim guidance on minimizing COVID-19 transmission risk ' 'when treating dental emergencies. ' 'https://www.ada.org/en/publications/ada-news/2020-archive/april/ada-releases-interim-guidance-on-minimizing-covid-19-transmission-risk-when-treating-emergencies ' '(2022).'}, { 'key': '24683_CR16', 'unstructured': 'Risk Management Principles for Dentistry. Resource outlining how to ' 'apply evidence-informed infection control measures within a broader ' 'risk-based approach. ' 'https://www.ada.org.au/Covid-19-Portal/Files/pdf/COVID-19-Risk-Management-Guidance.aspx ' '(2022).'}, { 'key': '24683_CR17', 'first-page': 'CD013626', 'volume': '9', 'author': 'MJ Burton', 'year': '2020', 'unstructured': 'Burton, M. J. et al. Use of antimicrobial mouthwashes (gargling) and ' 'nasal sprays by healthcare workers to protect them when treating ' 'patients with suspected or confirmed COVID-19 infection. Cochrane ' 'Database Syst. Rev. 9, CD013626 (2020).', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': '24683_CR18', 'first-page': 'CD013627', 'volume': '9', 'author': 'MJ Burton', 'year': '2020', 'unstructured': 'Burton, M. J. et al. Antimicrobial mouthwashes (gargling) and nasal ' 'sprays administered to patients with suspected or confirmed COVID-19 ' 'infection to improve patient outcomes and to protect healthcare workers ' 'treating them. Cochrane Database Syst. Rev. 9, CD013627 (2020).', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': '24683_CR19', 'doi-asserted-by': 'publisher', 'first-page': '314', 'DOI': '10.1016/j.ijid.2021.04.035', 'volume': '106', 'author': 'RCS Seet', 'year': '2021', 'unstructured': 'Seet, R. C. S. et al. Positive impact of oral hydroxychloroquine and ' 'povidone-iodine throat spray for COVID-19 prophylaxis: An open-label ' 'randomized trial. Int. J. Infect. Dis. 106, 314–322 (2021).', 'journal-title': 'Int. J. Infect. Dis.'}, { 'issue': '21', 'key': '24683_CR20', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2104547118', 'volume': '118', 'author': 'Q Yang', 'year': '2021', 'unstructured': 'Yang, Q. et al. Just 2% of SARS-CoV-2-positive individuals carry 90% of ' 'the virus circulating in communities. Proc. Natl. Acad. Sci. USA ' '118(21), e2104547118 (2021).', 'journal-title': 'Proc. Natl. Acad. Sci. USA'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-24683-8.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-24683-8', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-24683-8.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 11, 29]], 'date-time': '2022-11-29T02:20:17Z', 'timestamp': 1669688417000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-24683-8'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 11, 28]]}, 'references-count': 20, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['24683'], 'URL': 'http://dx.doi.org/10.1038/s41598-022-24683-8', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2022, 11, 28]]}, 'assertion': [ { 'value': '29 July 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '18 November 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 November 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '20449'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit